Collegium Pharmaceutical, Inc. Comprehensive Income
Collegium Pharmaceutical, Inc. (COLL) reported Comprehensive Income of -$14.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$14.83M, a 222.79% decline year-over-year.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $13.96M, a 436.23% increase year-over-year.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $16.99M, a 39.29% increase year-over-year.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $31.46M, a 217.48% increase year-over-year.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $63.13M, a 8.81% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $69.23M, a 43.73% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $48.17M.
- Collegium Pharmaceutical, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$25.00M, a 134.96% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.83M 10-Q · filed 2026-08-06 | -$874.00K 10-Q · filed 2026-08-06 | $16.12M derived: sum of 3 quarters · filed 2026-08-06 | $47.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.96M 10-Q · filed 2026-05-07 | $30.95M derived: sum of 2 quarters · filed 2026-05-07 | $62.41M derived: sum of 3 quarters · filed 2026-05-07 | $74.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $48.45M derived: sum of 2 quarters · filed 2026-02-26 | $60.53M derived: sum of 3 quarters · filed 2026-08-06 | $63.13M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.46M 10-Q · filed 2025-11-06 | $43.54M derived: sum of 2 quarters · filed 2026-08-06 | $46.14M 10-Q · filed 2025-11-06 | $58.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $12.08M 10-Q · filed 2026-08-06 | $14.68M 10-Q · filed 2026-08-06 | $26.88M derived: sum of 3 quarters · filed 2026-08-06 | $36.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.60M 10-Q · filed 2026-05-07 | $14.80M derived: sum of 2 quarters · filed 2026-05-07 | $24.71M derived: sum of 3 quarters · filed 2026-05-07 | $44.26M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.11M derived: sum of 2 quarters · filed 2026-02-26 | $41.66M derived: sum of 3 quarters · filed 2026-02-26 | $69.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.91M 10-Q · filed 2025-11-06 | $29.46M derived: sum of 2 quarters · filed 2025-11-06 | $57.03M 10-Q · filed 2025-11-06 | $89.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $19.55M 10-Q · filed 2025-08-07 | $47.12M 10-Q · filed 2025-08-07 | $79.13M derived: sum of 3 quarters · filed 2026-02-26 | $99.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $27.57M 10-Q · filed 2025-05-08 | $59.58M derived: sum of 2 quarters · filed 2026-02-26 | $80.20M derived: sum of 3 quarters · filed 2026-02-26 | $93.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $32.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.63M derived: sum of 2 quarters · filed 2026-02-26 | $65.59M derived: sum of 3 quarters · filed 2026-02-26 | $48.17M 10-K · filed 2026-02-26 |
| 2023-09-30 | $20.62M 10-Q · filed 2024-11-07 | $33.59M derived: sum of 2 quarters · filed 2024-11-07 | $16.16M 10-Q · filed 2024-11-07 | $8.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $12.97M 10-Q · filed 2024-08-08 | -$4.46M 10-Q · filed 2024-08-08 | -$11.66M derived: sum of 3 quarters · filed 2025-02-27 | -$11.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$17.43M 10-Q · filed 2024-05-09 | -$24.63M derived: sum of 2 quarters · filed 2025-02-27 | -$24.17M derived: sum of 3 quarters · filed 2025-02-27 | -$29.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$6.74M derived: sum of 2 quarters · filed 2025-02-27 | -$11.93M derived: sum of 3 quarters · filed 2025-02-27 | -$25.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $457.00K 10-Q · filed 2023-11-07 | -$4.73M derived: sum of 2 quarters · filed 2023-11-07 | -$17.80M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$5.19M 10-Q · filed 2023-08-03 | -$18.26M 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $71.52M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |